CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA

Kurlinkus, Benediktas; Ger, Marija; Kaupinis, Algirdas; Jasiūnas, Eugenijus; Valius, Mindaugas; Šileikis, Audrius

doi:10.3390/life11060542

Cited by 12 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this approach and verifying the data using individual gene expression data, we found that AGR2, CEACAM6, GNMT, PDIA2, POSTN, RBPJL, and S100P are upregulated in pancreatic tumor tissue as compared to non-tumor tissue from Black and White patients (Fig 1). The protein products from AGR2 [16,[23][24][25], CEAMAN6 [26][27][28], GNMT [29,30], PDIA2 [31,32], POSTN [17,33,34], RBPJL [35,36] and S100P [37][38][39] have been reported as potential diagnostic and prognostic biomarkers for pancreatic cancer or have demonstrated to be involved in either pancreatic cancer, initiation, migration, invasion, metastasis, or chemoresistance. This report provides additional evidence to support that these genes are specifically upregulated in pancreatic tumor tissue as compared to non-tumor tissue and their products could potentially serve as differentiating biomarkers in pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients

et al. 2023

View full text Add to dashboard Cite

In pancreatic cancer clinical trials, Black patients are under-represented while having higher morbidity and mortality rates as compared to other racial groups. Multiple factors, including socioeconomic and lifestyle factors may contribute to this disparity, but genomic contributions remain unclear. In an exploratory project to identify genes that may contribute to differences in survival between Black (n = 8) and White (n = 20) patients with pancreatic cancer, transcriptomic sequencing of over 24,900 genes was performed in human pancreatic tumor and non-tumor tissue obtained from Black and White patients. Over 4,400 genes were differentially expressed in tumor and non-tumor tissue, irrespective of race. To validate these results, the expression of four genes (AGR2, POSTN, TFF1, and CP) reported to be up-regulated in pancreatic tumor tissue as compared to non-tumor tissue were confirmed using quantitative PCR. Transcriptomic analysis that compared pancreatic tumor tissue from Black and White patients revealed differential expression in 1,200 genes, while a comparison of the non-tumor and tumor gene expression differences within each race revealed over 1,500 tumor-specific differentially expressed genes in pancreatic tumor and non-tumor tissue from Black patients. We identified TSPAN8 as a potential tumor-specific gene significantly overexpressed in pancreatic tumor tissue in Black patients as compared to White patients. Using Ingenuity Pathway Analysis software to compare the race-associated gene expression profiles, over 40 canonical pathways were identified to be potentially impacted by the gene expression differences between the races. Heightened expression of TSPAN8 was associated with poor overall survival, suggesting TSPAN8 as one potential genetic factor contributing to the differential outcomes in Black patients with pancreatic cancer, supporting the potential utility of larger genomic studies to further explore the role of TSPAN8 in pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[24][25][26][27][28][29]61 In addition, it could be used as a prognostic biomarker and some studies have evaluated the prognostic value of CEACAM6 serum levels in patients with cancer. [65][66][67] However, our study aimed to explore the prognostic role of CEACAM6 in human cancers, rather than in blood. With the potential role of CEACAM6 as immune checkpoint inhibitor in tumors, we focused this evaluation only on primary cancers.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic role CEACAM6 expression on patient outcome in cancer. Methods: A systematic search for studies evaluating the association between tumor expression of CEACAM6 and overall survival (OS) and disease-free survival (DFS) was performed. Hazard ratios (HR) were pooled in a meta-analysis using generic inverse variance and random effect modeling. Subgroup analyses were conducted based on tumor type and method of HR extraction. Results: Sixteen studies met the inclusion criteria. CEACAM6 expression was associated with worse OS [HR = 1.96, 95% confidence interval (CI) = 1.51–2.53], and DFS (HR = 2.49, 95% CI = 2.01–3.07) with subgroup analysis showing no significant differences between disease site subgroups. Conclusions: High expression of CEACAM6 is associated with worse OS and DFS in different malignancies. CEACAM6 is a target for the future development of novel therapeutics.

show abstract

“…CEACAM6 overexpression is generally associated with worse OS and DFS in a variety of solid tumors, 18 and serum CEACAM6 has been reported as a potential biomarker in pancreatic adenocarcinoma and plasma cell disorders. 19 , 20 , 21 In addition, Cao et al. 22 evaluated differentially expressed genes including CEACAM6 in peripheral blood exosomes as potential biomarkers for lung cancer; although the study was not quantitative, CEACAM6 exosome expression was higher in lung adenocarcinoma than in squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC

Piha‐Paul¹,

Simon²,

Belani³

et al. 2022

JTO Clinical and Research Reports

View full text Add to dashboard Cite

CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA

Cited by 12 publications

References 41 publications

Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients

Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients

Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC

Contact Info

Product

Resources

About